BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
- First Posted Date
- 2008-05-14
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 41
- Registration Number
- NCT00677313
- Locations
- ๐บ๐ธ
Research Site, Greenville, North Carolina, United States
๐บ๐ธLocal Institution, Reno, Nevada, United States
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
- Conditions
- Hedgehog PathwaySmoothenedBasal Cell Carcinoma (BCC)Basal Cell Nevoid Syndrome (BCNS)
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 53
- Registration Number
- NCT00670189
- Locations
- ๐บ๐ธ
Mayo Clinic Rochester, Rochester, Minnesota, United States
๐บ๐ธSouthwest Texas Addiction Research And Tech (Start) Center, San Antonio, Texas, United States
๐จ๐ฆLocal Institution, Toronto, Ontario, Canada
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT00664625
- Locations
- ๐บ๐ธ
Washington University School Of Medicine, St. Louis, Missouri, United States
๐บ๐ธUniversity Of Pennsylvania, Philadelphia, Pennsylvania, United States
๐ฆ๐ทLocal Institution, Buenos Aires, Argentina
A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 167
- Registration Number
- NCT00663208
- Locations
- ๐บ๐ธ
West Coast Clinical Trials, Llc, Cypress, California, United States
๐ต๐ทLocal Institution, Santurce, Puerto Rico
๐บ๐ธAdvanced Clinical Res Inst, Anaheim, California, United States
Phase IIIB Switching From Intravenous to Subcutaneous Study
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 123
- Registration Number
- NCT00663702
- Locations
- ๐บ๐ธ
Rheumatology Associates Of N. Al, P.C., Huntsville, Alabama, United States
๐บ๐ธDesert Medical Advances, Palm Desert, California, United States
๐บ๐ธValerius Medical Group &Research Ctr. Of Greater Long Beach, Long Beach, California, United States
Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.
- Conditions
- Kidney Cancer
- Interventions
- Biological: MDX 1411
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 27
- Registration Number
- NCT00656734
- Locations
- ๐บ๐ธ
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
๐บ๐ธBeth Israel Deaconness Medical Center, Boston, Massachusetts, United States
๐บ๐ธNevada Cancer Institute, Las Vegas, Nevada, United States
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: MDX-1100Biological: sterile saline for injection
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 110
- Registration Number
- NCT00656890
- Locations
- ๐บ๐ธ
Washington University School of Medicine, St. Louis, Missouri, United States
๐บ๐ธFlorida Medical Clinic-Tampa Clinic, Tampa, Florida, United States
๐บ๐ธChevy Chase Clinical Research, Chevy Chase, Maryland, United States
The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14
- Registration Number
- NCT00655746
- Locations
- ๐บ๐ธ
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT00651508
- Locations
- ๐บ๐ธ
Consultants In Blood Disorders & Cancer, Louisville, Kentucky, United States
Drug Interaction Study
- Conditions
- Antivirals/HIV
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 85
- Registration Number
- NCT00646776
- Locations
- ๐บ๐ธ
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States